The overall goal of the proposed study is the discovery and preclinical validation of novel targets associated with molecular processes that lead to cognitive decline, the primary outcome of most AD trials. The recent NIA Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention that led to the RFA to which we are responding, made a number of recommendations which motivated the strategy adopted in the proposed study. Our proposal brings together an exceptionally strong and unique multi-disciplinary team with the relevant skills needed to achieve our overall goal.
In Aim 1, we take a systems biology approach to mine a truly unique set of deep clinical, paraclinical, pathologic, genomic, epigenomic, and transcriptomic data assembled from frozen dorsolateral prefrontal cortex brain tissue of 1000 subjects from two cohort studies of aging and dementia, the Religious Order Study and the Memory and Aging Project, in conjunction with other publicly available functional datasets. These unique data provide an excellent substrate for the identification and nomination of molecular targets for drug discovery. Target discovery is coupled with a flexible translational strategy that first validates targets by a targeted proteomic study of brain tissue from the same region and subjects in Aim 2.
In Aim 3, an RNA interference (RNAi) and overexpression functional validation study in cultured human neurons and astrocytes is executed in parallel in Aim 3. Finally, these data come together in Aim 4 which performs high throughput small molecule screens on neurons and astrocytes derived from induced pluripotent stem cells (iPSC) on the most promising targets. Our proposal is ambitious but realistic: it reflects the deployment of cutting-edge approaches with a practical mindset in which redundancies have been carefully considered to mitigate risk and ensure the delivery of data, network models and lead compounds. The proposed study will discover and validate novel targets associated with molecular processes that lead to cognitive decline, and it will demonstrate the druggability of one or more targets, setting the stage for clinical trials with new and novel approaches to the prevention and treatment of AD.

Public Health Relevance

The prevention and treatment of AD is a major public health priority. However, novel therapeutic targets are urgently needed. The proposed study will leverage deep phenotypic and multi-level -omics data to identify novel therapeutic targets, functionally validate and subsequently demonstrate the druggability of a number of selected targets, thereby filling an important gap between the new generation of -omics technology and the identification of novel and druggable targets to move to preclinical or clinical trials.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6 (A1))
Program Officer
Petanceska, Suzana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Broad Institute, Inc.
United States
Zip Code
Miller, Jeremy A; Guillozet-Bongaarts, Angela; Gibbons, Laura E et al. (2017) Neuropathological and transcriptomic characteristics of the aged brain. Elife 6:
Patrick, Ellis; Rajagopal, Sathyapriya; Wong, Hon-Kit Andus et al. (2017) Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer's disease. Mol Neurodegener 12:51
Sullivan, Sarah E; Young-Pearse, Tracy L (2017) Induced pluripotent stem cells as a discovery tool for Alzheimer?s disease. Brain Res 1656:98-106
Yu, Lei; Dawe, Robert J; Boyle, Patricia A et al. (2017) Association Between Brain Gene Expression, DNA Methylation, and Alteration of Ex Vivo Magnetic Resonance Imaging Transverse Relaxation in Late-Life Cognitive Decline. JAMA Neurol 74:1473-1480
Barral, S; Habeck, C; Gazes, E et al. (2017) A Dopamine Receptor genetic variant enhances perceptual speed in cognitive healthy subjects. Alzheimers Dement (N Y) 3:254-261
Chibnik, L B; White, C C; Mukherjee, S et al. (2017) Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Mol Psychiatry :
Yu, Lei; Chibnik, Lori B; Yang, Jingyun et al. (2016) Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer's disease pathology. Alzheimers Dement 12:942-951
Farfel, Jose M; Yu, Lei; De Jager, Philip L et al. (2016) Association of APOE with tau-tangle pathology with and without ?-amyloid. Neurobiol Aging 37:19-25
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Buchman, Aron S; Yu, Lei; Boyle, Patricia A et al. (2016) Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 86:735-41

Showing the most recent 10 out of 28 publications